source
- AbbVie’s etentamig shows strong survival and response gains in Phase 3 multiple myeloma trialAbbVie reported that its investigational bispecific T‑cell engager, etentamig, significantly reduced the risk of disease progression or death in a Phase 3 study of patients with relapsed or refract…
- Experts say Angelman syndrome drug failure leaves hope for similar antisense therapiesUltragenyx announced that its late-stage trial of an experimental Angelman syndrome drug did not meet its primary endpoints, marking a setback for the rare-disease community. Researchers such as M…